AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11826546
Drug: Fosinopril 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 10, 20, and 40 mg as monotherapy
Trial: 8034781
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel + SCRP
Trial: 2539025
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus dihydroergotamine mesylate (5,000 IU unfractionated heparin plus 0.5 mg dihydroergotamine mesylate twice daily)
Trial: 2539025
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin plus dihydroergotamine mesylate (1,500 IU low-molecular weight heparin plus 0.5 mg dihydroergotamine mesylate once daily)
Trial: 2539025
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin plus dihydroergotamine mesylate
Trial: 2539025
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus dihydroergotamine mesylate
Trial: 29330978
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection for sensory blockade
Trial: 23735819
Drug: Epoetin-alfa (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alfa (average weekly doses ranging from 133 to 19,106 units/week)
Trial: 23735819
Drug: Epoetin-alfa (middle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alfa (middle tertile of Hb achieved >11.5 to <12.7 g/dl and lowest tertile of epoetin-alfa dose exposure level <5,164 units/week)
Trial: 23735819
Drug: Epoetin-alfa (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alfa (average weekly dose)
Trial: 16422971
Drug: Vardenafil 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10/20 mg
Trial: 29864043
Drug: Electrical dry
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical dry needling, manual therapy (MT), and exercise
Trial: 29864043
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) and exercise
Trial: 26186644
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of pitavastatin calcium
Trial: 26186644
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of pitavastatin calcium
Trial: 23878024
Drug: Modified grapefruit
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified grapefruit juice (GFJ) (240 mL)
Trial: 23878024
Drug: Original grapefruit
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original grapefruit juice (GFJ) (240 mL)
Trial: 20185386
Drug: Etanercept 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 0.8 mg/kg (<= 50 mg) once weekly for 12 weeks
Trial: 18185506
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (iPTH) levels maintained in the target range of 150-300 pg ml(‐1)
Trial: 18185506
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (iPTH) levels less than 150 pg ml(‐1)
Trial: 18185506
Drug: Intact parathyroid
RxNorm normalized name: Intact parathyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact parathyroid hormone (iPTH) levels greater than 300 pg ml(‐1)
Trial: 10514345
Drug: Recombinant glucagon
RxNorm normalized name: Glucagon recombinant
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant glucagon (rG) pH 2.0 administered intramuscularly (im)
Trial: 10514345
Drug: Recombinant glucagon
RxNorm normalized name: Glucagon recombinant
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant glucagon (rG) pH 2.0 administered subcutaneously (sc)
Trial: 8949429
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream (50 micrograms/g once daily)
Trial: 8949429
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream twice daily
Trial: 8949429
Drug: Calcipotriol and
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol and clobetasone 17-butyrate (0.5 mg/g) creams
Trial: 8949429
Drug: Calcipotriol and
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol and betamethasone 17-valerate (1 mg/g) creams
Trial: 8949429
Drug: Calcipotriol monotherapy
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol monotherapy (once daily)
Trial: 28702809
Drug: Racemic formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic formoterol (2 × 27 µg)
Trial: 24963111
Drug: Salsalate (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate (3.5 g daily for 4 weeks)
Trial: 22704274
Drug: GPs' treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPs' treatment effect
Trial: 22267373
Drug: Letrozole 5
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 5 mg daily for 5 days
Trial: 19089782
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily for 5 days
Trial: 17879495
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs with oral prednisolone (1 mg/kg body weight for 7 days, tapering off over 3 days)
Trial: 17879495
Drug: Antiepileptic monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic monotherapy
Trial: 15080019
Drug: ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (4 mg IV and 16 mg in PCA pump)
Trial: 12479110
Drug: Tramadol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Trial: 12479110
Drug: Morphine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.12 mg/kg) and 0.125% bupivacaine (100 ml) for 48 hours
Trial: 12479110
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tramadol (6 mg/kg), morphine (0.12 mg/kg), and 0.125% bupivacaine (100 ml) for 48 hours
Trial: 3674580
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 800 micrograms per day
Trial: 3674580
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) changed to oral theophylline
Trial: 24955452
Drug: Monthly endoscopic
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly endoscopic variceal ligation (EVL)
Trial: 23341517
Drug: Chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT) with concurrent cisplatin 100 mg/m(2) on days 1, 22, and 43 of RT (arm A)
Trial: 23341517
Drug: Bioradiotherapy (BRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioradiotherapy (BRT) with concurrent cetuximab 400 mg/m(2) loading dose and 250 mg/m(2) per week during RT (arm B)
Trial: 18822428
Drug: Milrinone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (loading dose 0.75 microg/kg/min for 3 hours then maintenance 0.2 microg/kg/min until 18 hours after birth)
Trial: 8995087
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of aspirin or anticoagulant therapy
Trial: 8995087
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents and captopril
Trial: 30763405
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment before immunisation
Trial: 30763405
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment at immunisation
Trial: 29547049
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (de novo group)
Trial: 29547049
Drug: Lanreotide 120
RxNorm normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 120 mg subcutaneously every 4 weeks for 16 weeks (prior octreotide group)
Trial: 24338935
Drug: Spironolactone (titrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (titrating dose, 12.5-50 mg once daily)
Trial: 24338935
Drug: Clonidine (titrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (titrating dose, 0.1-0.3 mg twice daily)
Trial: 23198694
Drug: Chinese diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese diabetes group visit program (12 monthly group visit sessions)
Trial: 17403121
Drug: rosiglitazone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone + metformin (8/2000 mg)
Trial: 11136485
Drug: Potassium canrenoate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate, 50 mg once daily
Trial: 7935635
Drug: Radioiodinated vasoactive
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodinated vasoactive intestinal peptide (VIP) administered as a single intravenous bolus injection (300 pmol [1 microgram])
Trial: 23617693
Drug: Isotretinoin 5
RxNorm normalized name: isotretinoin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 5 mg/day for 16 weeks
Trial: 23617693
Drug: Isotretinoin 5
RxNorm normalized name: isotretinoin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 5 mg/day after 16 weeks of placebo
Trial: 23617693
Drug: Isotretinoin 5
RxNorm normalized name: isotretinoin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 5 mg/day for 32 weeks
Trial: 17655947
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin (low dose)
Trial: 17655947
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin (high dose)
Trial: 12462550
Drug: Estrogen-progestin replacement
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progestin replacement therapy (HRT)
Trial: 7740333
Drug: IV vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vinorelbine (first-line therapy)
Trial: 2201742
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg every 12 h for 5 days
Trial: 2201742
Drug: Ampicillin, 500
RxNorm normalized name: Ampicillin, 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 500 mg every 6 h for 5 days
Trial: 7026260
Drug: Sublingual isoxsuprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual isoxsuprine 20 mg
Trial: 7026260
Drug: Oral isoxsuprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isoxsuprine 20 mg
Trial: 28526720
Drug: Trabectedin 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.2 mg/m2
Trial: 23722126
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel applied twice a day for one week
Trial: 23722126
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel applied twice a day for one week
Trial: 21321426
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of Panax ginseng (PG)
Trial: 19761681
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day)
Trial: 19761681
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day)
Trial: 11273588
Drug: FUFOL (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUFOL (monthly regimen)
Trial: 10896408
Drug: Halofantrine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (1500 mg)
Trial: 10896408
Drug: Chloroquine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (1500 mg)
Trial: 354330
Drug: Conventional amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional amitriptyline tablets (Saroten)
Trial: 26840887
Drug: Collagen hydrolysate
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen hydrolysate with a lower content of bioactive collagen peptides (L-CP)
Trial: 16000280
Drug: 123I‐PE2I bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 123I‐PE2I bolus injection
Trial: 16000280
Drug: Combined bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bolus and constant infusion of 123I‐PE2I
Trial: 12833584
Drug: Candesartan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (4 mg, once daily) in combination with ramipril
Trial: 12833584
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with ramipril
Trial: 10567194
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of sustained‐release nicardipine hydrochloride twice daily
Trial: 10567194
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of trichlormethiazide once daily
Trial: 1818788
Drug: Nitrate therapy
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate therapy
Trial: 24663014
Drug: Overall pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall pharmacokinetics of rifampin and isoniazid
Trial: 12789223
Drug: Other Antihistamines
RxNorm normalized name: Other antihistamines for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Antihistamines (OAH)
Trial: 12789223
Drug: Other Antihistamines
RxNorm normalized name: Other antihistamines for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Antihistamines (OAH) (first trimester)
Trial: 9082488
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment for primary prevention of coronary heart disease
Trial: 1634452
Drug: Theolan preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolan preparation (once a day)
Trial: 1634452
Drug: Theolan preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolan preparation (twice a day)
Trial: 6499384
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate with bisacodyl (oral or rectal)
Trial: 25237668
Drug: Computer-guided implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-guided implant placement aided with templates
Trial: 25237668
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant placement without templates
Trial: 8683286
Drug: Nimodipine treatment
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine treatment (intravenous and oral) for 3 weeks
Trial: 8683286
Drug: Nimodipine treatment
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine treatment (intravenous and oral) for 3 weeks (compliant patients only)
Trial: 1803712
Drug: Estrogen Receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen Receptor (ER) positive status
Trial: 1803712
Drug: Estrogen Receptor
RxNorm normalized name: Estrogen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen Receptor (ER) levels greater than 100 fmol/mg protein
Trial: 1803712
Drug: Progesterone Receptor
RxNorm normalized name: Progesterone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone Receptor (PgR) status
Trial: 1803712
Drug: Progesterone Receptor
RxNorm normalized name: Progesterone receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone Receptor (PgR) levels
Trial: 6360027
Drug: Methysergide, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methysergide, 8 mg daily
Trial: 27302362
Drug: EGCG (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (9 mg/kg per day) plus cognitive training
Trial: 12809958
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg QD
Trial: 12809958
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg QD
Trial: 9129860
Drug: Lovastatin monotherapy
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin monotherapy
Trial: 1548825
Drug: Aztreonam 100
RxNorm normalized name: aztreonam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam 100 mg three times a day for 5 days
Trial: 30299178
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root (1.425 g/day)
Trial: 29809257
Drug: Osteopathic Manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manipulative Therapy (OMTh)
Trial: 15701612
Drug: Betamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (4 mL of 2% xylocaine and 1 mL (6 mg) of betamethasone)
Trial: 15701612
Drug: Xylocaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylocaine (5 mL of 2% xylocaine alone)
Trial: 10847423
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg alcohol in orange-flavoured drink
Trial: 8925753
Drug: AVE micro-stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE micro-stent implantation with dual antiaggregation treatment (500 mg ticlopidine and 100 mg aspirin daily for 6 weeks)
Trial: 7709692
Drug: human follicular
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: human follicular fluid (hFF) treatment
Trial: 7709692
Drug: mini‐CDPG treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini‐CDPG treatment
Trial: 29673355
Drug: Mirabegron (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (25 mg for 4 weeks, then 50 mg for 4 weeks)
Trial: 29673355
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER (4 mg for 8 weeks)
Trial: 26921934
Drug: Multicomponent non‐pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent non‐pharmacologic intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drug chart review, elimination, oxygenation, pain)
Trial: 23545834
Drug: GnRH-antagonist protocol
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH-antagonist protocol with highly purified uFSH (Bravelle®) 300 IU/day and 0.25 mg/day GnRH-antagonist starting on cycle day 19-21
Trial: 23545834
Drug: Conventional GnRH-antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional GnRH-antagonist protocol with 150-225 rFSH or HP-HMG/day
Trial: 10653877
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus cisplatin (135 mg/m² and 250 mg/m²)
Trial: 10653877
Drug: Etoposide plus
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide plus cisplatin (100 mg/m² daily on days 1 to 3, with cisplatin 75 mg/m²)
Trial: 29587582
Drug: Upfront spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upfront spironolactone 25 mg OD
Trial: 29587582
Drug: Discharge spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discharge spironolactone 25 mg OD
Trial: 20795383
Drug: Immunovac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunovac vaccine with basic therapy